Paragon Bioservices is a contract research and manufacturing organization focused on accelerating development and manufacturing of biopharmaceuticals and vaccines. The company provides research services, process development, and cGMP manufacturing including production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. Its cGMP facilities include microbial and mammalian suites, fill-finish capability, and fully segregated virus and BSL-3 areas. Paragon is led by CEO Marco Chacon and COO Peter L. Buzy and was founded in 1990. The company is using newly raised capital to accelerate growth.

Total raised

$13M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2014